Compare SXC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | CTMX |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | 848 | 69 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.2M | 716.9M |
| IPO Year | 2011 | 2015 |
| Metric | SXC | CTMX |
|---|---|---|
| Price | $9.69 | $3.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $9.00 | ★ $12.10 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,600,300,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | $94.00 | ★ $22.58 |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $1.90 |
| 52 Week High | $9.92 | $8.21 |
| Indicator | SXC | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 47.01 |
| Support Level | $7.52 | $3.01 |
| Resistance Level | $9.79 | $3.55 |
| Average True Range (ATR) | 0.37 | 0.15 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 83.12 | 31.17 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.